Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 48,099,644
  • Shares Outstanding, K 300,210
  • Annual Sales, $ 11,397 M
  • Annual Income, $ 327,400 K
  • 36-Month Beta 1.60
  • Price/Sales 4.29
  • Price/Cash Flow 9.94
  • Price/Book 1.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
158.54 +3.46%
on 07/20/17
176.32 -6.97%
on 06/22/17
-6.72 (-3.94%)
since 06/21/17
3-Month
158.54 +3.46%
on 07/20/17
192.15 -14.63%
on 05/18/17
-7.91 (-4.60%)
since 04/21/17
52-Week
158.54 +3.46%
on 07/20/17
209.22 -21.60%
on 09/20/16
-29.43 (-15.21%)
since 07/21/16

Most Recent Stories

More News
New Strong Sell Stocks for July 20th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

ZEUS : 17.56 (-3.20%)
DCP : 34.55 (-1.57%)
ARRY : 8.24 (-1.67%)
AKAM : 52.13 (-0.44%)
SHPG : 164.03 (+2.38%)
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody

Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody

SHPG : 164.03 (+2.38%)
The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire

The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire

CELG : 137.74 (+1.05%)
MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
SHPG : 164.03 (+2.38%)
GILD : 73.76 (+0.46%)
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.

CELG : 137.74 (+1.05%)
MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
SHPG : 164.03 (+2.38%)
GILD : 73.76 (+0.46%)
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

ENZ : 11.35 (-1.05%)
SHPG : 164.03 (+2.38%)
ABBV : 74.63 (+0.84%)
RHHBY : 32.2700 (+0.22%)
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

ENZ : 11.35 (-1.05%)
ALNY : 82.02 (+1.88%)
SHPG : 164.03 (+2.38%)
SNY : 47.71 (-0.73%)
Alnylam Commences Phase III Study for Hemophilia Candidate

Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.

ENZ : 11.35 (-1.05%)
ALNY : 82.02 (+1.88%)
SHPG : 164.03 (+2.38%)
SNY : 47.71 (-0.73%)
Shire Completes NDA Filing for Hemophilia Drug with FDA

Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654,...

ENZ : 11.35 (-1.05%)
BMRN : 89.28 (+1.76%)
SHPG : 164.03 (+2.38%)
RHHBY : 32.2700 (+0.22%)
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the...

VKTX : 1.15 (+3.60%)
AUPH : 6.55 (-0.76%)
SHPG : 164.03 (+2.38%)
KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.

VVUS : 1.24 (+1.64%)
KMPH : 3.50 (-2.78%)
SHPG : 164.03 (+2.38%)
MEIP : 3.02 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Support & Resistance

2nd Resistance Point 168.48
1st Resistance Point 166.25
Last Price 164.03
1st Support Level 160.82
2nd Support Level 157.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.